Pharmaceutical Industry discussion, review, analysis, news and information. |
« PDL BioPharma Presented Physician Survey Results on Heart Attack Treatment | Main | Nabi Biopharmaceuticals’ PhosLo® EPICK Study Revealed Positive Results »
|
Oct17
|
 Memory was improved to pre-injury levels (100%), a statistically significant effect (p<0.03). The following being the key points obtained: These preclinical data suggests that NNZ-2591 has the capacity to improve learning and memory processes after short-term treatment, extending the potential application of NNZ-2591 as a treatment for dementias such as those associated with over 50% of Parkinson's disease patients. Find more details from Neuren’s press release (a pdf file). |
TrackBack URL for this entry:
« PDL BioPharma Presented Physician Survey Results on Heart Attack Treatment | Main | Nabi Biopharmaceuticals’ PhosLo® EPICK Study Revealed Positive Results »
Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!
BIZZlogos - Add your logo - free link to your site| View Network Map Network Feed List (OPML) Know More Media Network Feed |
PharmaGazette is a member of the Know More Media network of business related blogs.
Here are some current headlines from some of our business publications:
ProductivityGoal | CallCenterScript |
AdHurl | TheBizofKnowledge |
LandingTheDeal | CustomersAreAlways |
HealthCareVox | BrainBasedBusiness |
TheInsurancePolicy | MarketingBlurb |
Write for us About us Contact Advertise Privacy Disclaimer
This weblog is licensed under a Creative Commons License.
Comment Preview